Jean‐Nicolas Vauthey

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Matthew H. G. Katz · 26 shared papers, 2012–2023 · strength 1.53
   • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
   • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
   • Paper Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoa… DOI 10.1016/j.hpb.2019.01.011↗
2. Jeffrey E. Lee · 26 shared papers, 2012–2023 · strength 1.53
   • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
   • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
   • Paper Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoa… DOI 10.1016/j.hpb.2019.01.011↗
3. Ching-Wei David Tzeng · 14 shared papers, 2012–2023 · strength 1.14
   • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
   • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
   • Paper Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoa… DOI 10.1016/j.hpb.2019.01.011↗
4. Michael P. Kim · 11 shared papers, 2016–2023 · strength 1.05
   • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
   • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
   • Paper Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoa… DOI 10.1016/j.hpb.2019.01.011↗
5. Jason B. Fleming · 19 shared papers, 2012–2019 · strength 0.74
   • Paper Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Ident… DOI 10.1016/j.hpb.2018.10.018↗
   • Paper Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with… DOI 10.1002/jso.25067↗
   • Paper Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal A… DOI 10.1001/jamasurg.2017.2227↗
6. Laura R. Prakash · 7 shared papers, 2016–2022 · strength 0.59
   • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
   • Paper Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenoca… DOI 10.1016/j.hpb.2018.10.009↗
   • Paper Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Ident… DOI 10.1016/j.hpb.2018.10.018↗
7. Gauri Rajani Varadhachary · 13 shared papers, 2012–2019 · strength 0.49
   • Paper Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Aden… DOI 10.1097/mpa.0000000000001345↗
   • Paper Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal A… DOI 10.1001/jamasurg.2017.2227↗
   • Paper Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. DOI 10.1007/s11605-016-3286-9↗
8. Robert A. Wolff · 12 shared papers, 2012–2017 · strength 0.40
   • Paper Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal A… DOI 10.1001/jamasurg.2017.2227↗
   • Paper Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. DOI 10.1007/s11605-016-3286-9↗
   • Paper Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic ca… DOI 10.1245/s10434-014-4192-6↗
9. Peter W. T. Pisters · 12 shared papers, 2012–2015 · strength 0.37
   • Paper Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic ca… DOI 10.1245/s10434-014-4192-6↗
   • Paper Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable an… DOI 10.1007/s11605-013-2374-3↗
   • Paper Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline rese… DOI 10.1111/hpb.12154↗
10. Huamin Wang · 10 shared papers, 2012–2017 · strength 0.33
    • Paper Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal A… DOI 10.1001/jamasurg.2017.2227↗
    • Paper Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic ca… DOI 10.1245/s10434-014-4192-6↗
    • Paper Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable an… DOI 10.1007/s11605-013-2374-3↗
11. Christopher H. Crane · 10 shared papers, 2012–2016 · strength 0.33
    • Paper Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. DOI 10.1007/s11605-016-3286-9↗
    • Paper Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic ca… DOI 10.1245/s10434-014-4192-6↗
    • Paper Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable an… DOI 10.1007/s11605-013-2374-3↗
12. Timothy Eric Newhook · 2 shared papers, 2022–2023 · strength 0.32
    • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
    • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
13. Naruhiko Ikoma · 2 shared papers, 2022–2023 · strength 0.32
    • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
    • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
14. David R. Fogelman · 6 shared papers, 2012–2019 · strength 0.29
    • Paper Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Aden… DOI 10.1097/mpa.0000000000001345↗
    • Paper Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal A… DOI 10.1001/jamasurg.2017.2227↗
    • Paper Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. DOI 10.1007/s11605-016-3286-9↗
15. Yun Shin Chun · 2 shared papers, 2019–2023 · strength 0.27
    • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
    • Paper Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. DOI 10.1245/s10434-018-07093-x↗
16. Hop S. Tran Cao · 3 shared papers, 2014–2023 · strength 0.24
    • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
    • Paper Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable an… DOI 10.1007/s11605-013-2374-3↗
    • Paper Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on mult… DOI 10.1007/s11605-013-2412-1↗
17. Graciela M. Nogueras‐González · 4 shared papers, 2012–2019 · strength 0.23
    • Paper Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Ident… DOI 10.1016/j.hpb.2018.10.018↗
    • Paper Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with… DOI 10.1002/jso.25067↗
    • Paper Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable an… DOI 10.1007/s11605-013-2374-3↗
18. James L. Abbruzzese · 7 shared papers, 2012–2014 · strength 0.19
    • Paper Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on mult… DOI 10.1007/s11605-013-2412-1↗
    • Paper Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first … DOI 10.1016/j.jamcollsurg.2012.03.024↗
    • Paper Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenoc… DOI 10.1002/cncr.26651↗
19. Ève Simoneau · 2 shared papers, 2019 · strength 0.19
    • Paper Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoa… DOI 10.1016/j.hpb.2019.01.011↗
    • Paper Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. DOI 10.1245/s10434-018-07093-x↗
20. Jordan M. Cloyd · 3 shared papers, 2016–2019 · strength 0.19
    • Paper Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensit… DOI 10.1097/mpa.0000000000001231↗
    • Paper Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal A… DOI 10.1001/jamasurg.2017.2227↗
    • Paper Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. DOI 10.1007/s11605-016-3286-9↗
21. Yongwoo David Seo · 1 shared paper, 2023 · strength 0.17
    • Paper Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. DOI 10.1002/jhbp.1218↗
22. Aparna Balachandran · 5 shared papers, 2012–2015 · strength 0.15
    • Paper Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic … DOI 10.1245/s10434-014-4285-2↗
    • Paper Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline rese… DOI 10.1111/hpb.12154↗
    • Paper Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenoc… DOI 10.1245/s10434-011-2211-4↗
23. Federico Oppliger · 1 shared paper, 2022 · strength 0.15
    • Paper AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatme… DOI 10.1016/j.suronc.2021.101673↗
24. Douglas B. Evans · 4 shared papers, 2012–2015 · strength 0.14
    • Paper Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic … DOI 10.1245/s10434-014-4285-2↗
    • Paper Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable an… DOI 10.1007/s11605-013-2374-3↗
    • Paper Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on mult… DOI 10.1007/s11605-013-2412-1↗
25. Andrew J. Lee · 1 shared paper, 2019 · strength 0.10
    • Paper Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoa… DOI 10.1016/j.hpb.2019.01.011↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.